Format

Send to

Choose Destination
Front Cardiovasc Med. 2019 Mar 28;6:29. doi: 10.3389/fcvm.2019.00029. eCollection 2019.

MEF2 and the Right Ventricle: From Development to Disease.

Author information

1
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT, United States.
2
Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States.
3
Choate Rosemary Hall, Wallingford, CT, United States.
4
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, United States.

Abstract

Pulmonary arterial hypertension is a progressive and ultimately life-limiting disease in which survival is closely linked to right ventricular function. The right ventricle remains relatively understudied, as it is known to have key developmental and structural differences from the left ventricle. Here, we will highlight what is known about the right ventricle in normal physiology and in the disease state of pulmonary arterial hypertension. Specifically, we will explore the role of the family of MEF2 (myocyte enhancer factor 2) transcription factors in right ventricular development, its response to increased afterload, and in the endothelial dysfunction that characterizes pulmonary arterial hypertension. Finally, we will turn to review potentially novel therapeutic strategies targeting these pathways.

KEYWORDS:

HDAC; MEF2; hypertrophy; pulmonary hypertension; right ventricle

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center